This pancreatic cancer drug is so good, it got a standing ovation | Lisa Jarvis

Researchers announced a promising new therapy for pancreatic cancer that has significant improvements in patient survival during trials. The treatment, delivered through a novel delivery system, targets cancer cells while sparing healthy tissue, reducing side effects. In a recent conference, specialists highlighted the drug’s ability to extend overall survival by nearly 30% compared with standard care. The data also indicated a reduction in tumor size in a majority of participants, with manageable toxicity profiles. Experts emphasized the importance of early detection and suggested that this therapy could become a cornerstone of future pancreatic cancer management, pending further validation in studies.